Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
41.76B
Market cap41.76B
Price-Earnings ratio
137.55
Price-Earnings ratio137.55
Dividend yield
Dividend yield
Average volume
1.16M
Average volume1.16M
High today
$322.02
High today$322.02
Low today
$312.67
Low today$312.67
Open price
$317.50
Open price$317.50
Volume
1.02M
Volume1.02M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

The current Alnylam Pharmaceuticals(ALNY) stock price is $314.00, with a market capitalization of 41.76B. The stock trades at a price-to-earnings (P/E) ratio of 137.55.

On 2026-03-19, Alnylam Pharmaceuticals(ALNY) stock moved within a range of $312.67 to $322.02. With shares now at $314.00, the stock is trading +0.4% above its intraday low and -2.5% below the session's peak.

Trading activity shows a volume of 1.02M, compared to an average daily volume of 1.16M.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

ALNY News

Simply Wall St 24h
Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY

Earlier this month, Tenaya Therapeutics announced a research collaboration with Alnylam Pharmaceuticals to validate up to 15 gene targets for cardiovascular dis...

Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY
Simply Wall St 2d
A Look At Alnylam Pharmaceuticals Valuation After New Tenaya Cardiovascular Partnership

Advertisement Tenaya partnership broadens Alnylam’s reach into cardiovascular research The new collaboration between Alnylam Pharmaceuticals (ALNY) and Tenaya...

A Look At Alnylam Pharmaceuticals Valuation After New Tenaya Cardiovascular Partnership
TipRanks 3d
Alnylam downgraded to Hold from Buy at Jefferies

Jefferies downgraded Alnylam (ALNY) to Hold from Buy with a price target of $330, down from $522, after assuming coverage of the name. The firm is “impressed” w...

Analyst ratings

71%

of 28 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.